about
The clinical efficacy of artemether/lumefantrine (Coartem)Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugsMisclassification of drug failure in Plasmodium falciparum clinical trials in southeast AsiaIncreased fluidity and oxidation of malarial lipoproteins: relation with severity and induction of endothelial expression of adhesion moleculesPopulation pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patientsDeployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria InitiativeAn open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in AsiaTransient lesion in the splenium of the corpus callosum in acute uncomplicated falciparum malaria.Heritability of P. falciparum and P. vivax malaria in a Karen population in Thailand.Changes in platelet count in uncomplicated and severe falciparum malaria.Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African childrenWhole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria.Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodesPrimaquine administration after falciparum malaria treatment in malaria hypoendemic areas with high incidence of falciparum and vivax mixed infection: pros and cons.Appropriate time for primaquine treatment to reduce Plasmodium falciparum transmission in hypoendemic areas.Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia.Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.Tolerability of ivermectin in gnathostomiasis.Management of malaria in Thailand.N-acetylcysteine in severe falciparum malaria in Thailand.Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malariaDefective erythropoietin production and reticulocyte response in acute Plasmodium falciparum malaria-associated anemia.Clinical experience with intravenous quinine, intramuscular artemether and intravenous artesunate for the treatment of severe malaria in Thailand.Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.Hyponatraemia and hypokalaemia in adults with uncomplicated malaria in Thailand.High-dose primaquine regimens against relapse of Plasmodium vivax malaria.Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand.Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects.In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia.Evaluation of the NOW Malaria Immunochromatographic Test for Quantitative Diagnosis of Falciparum and Vivax Malaria Parasite DensityActivation of nuclear factor kappa B in peripheral blood mononuclear cells from malaria patients.A common TLR1 polymorphism is associated with higher parasitaemia in a Southeast Asian population with Plasmodium falciparum malaria.Increased synapsin I expression in cerebral malariaGenetic diversity among Plasmodium vivax isolates along the Thai-Myanmar border of ThailandTravelers' malaria among foreigners at the Hospital for Tropical Diseases, Bangkok, Thailand - a 6-year review (2000-2005).A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and AfricaUse of buffy coat thick films in detecting malaria parasites in patients with negative conventional thick films.Suppression of Plasmodium falciparum by serum collected from a case of Plasmodium vivax infection.Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
P50
Q21034141-3C4955E2-2E7E-4CCD-9433-E57787A39F8FQ24642214-11D83C38-B098-4A41-8C32-0D732DD9CD27Q24653304-BAF2BD01-E75A-4F38-9B92-8652ED46CB9CQ24802371-DFC408E7-53AD-412D-9EB6-8B89DE6C0C89Q28469076-D3530F63-BF22-47AB-B59A-360C1012FDADQ28469264-64D1069C-3248-4E4C-AE87-CCA805789288Q28474978-6DF881E2-33AA-40B4-B1FC-6B3E80282042Q30774424-967E3A60-F46B-47BC-9C68-2011F6A74E48Q33390376-EE8D44B0-5907-42BE-825C-BD804350CBD4Q33392797-57ECB7A0-2A49-49DC-8F14-76AFB64A3AA0Q33419878-0DEC0527-FD3A-4496-BC03-C85EAD9D15B7Q33590171-72CF99F3-FF44-4C1C-931C-0E5F8FA67C55Q33743556-04545292-80C4-4D10-9689-5291F046AC13Q33942754-D67E0A28-2628-4C24-8C78-DAFE82C2FE90Q33942758-7EF66F99-B778-4151-BFE3-8626310955DFQ34030210-44B6A72C-AB86-481C-ABC7-AE517852A418Q34393524-47060A50-AC19-4B87-83F1-4CF61D610C67Q34446009-8B7CB431-AE85-4666-8F7F-3370C7CAF98EQ34596815-1D8B843E-0C4A-450A-BA28-7A71B7B8C335Q35043509-B028A53A-C10A-4366-A2AC-FAAD3F3C537FQ35043511-BE6D9B5E-555C-4C18-B89F-C94147650A70Q35043519-21445C6A-9EF9-47B8-B761-0F377F2C82E6Q35043526-C581035A-22ED-4E63-BC62-066080751477Q35069117-E9326601-A8F2-41A6-A866-A9712B006139Q35069122-B0C93727-3725-43AC-A8E6-C1ADD0F0C1CDQ35086211-3B84B757-7EE6-4269-A2F0-E5A23E0C383DQ35086214-7EDBF4A8-0C6B-4260-995C-A7BA42D17DA3Q35140594-64259E1F-FDD5-468F-A90E-6C5DBF5A7EF8Q35635904-A0271D1C-36DA-4107-8F25-568917427536Q35647764-65B3196B-190C-4FC3-91DF-576D443F07B8Q35786811-73E0607C-D737-4FFB-A6C3-15494848D6C6Q36173345-6B809398-D0EF-49D7-B992-1DDC003E289DQ36439212-1595614F-5685-4FBE-83BD-FA1760697A24Q36464315-9D16FD86-0E0E-4BD7-B7AE-D20A1A34AC68Q36560648-98EE6339-3894-4F53-A79A-D8E9DF4BD8FAQ36591966-F8076959-E531-4579-8E8B-726C8C94BD11Q36715829-679DB9A2-313B-4145-9B5F-D9744BCF9C3AQ36719670-11BA4B3E-B0D0-46E6-92A7-89DAE411D910Q36743839-8B5BFFF6-9266-4C3A-A196-2B229F9F909AQ36853749-3AED3D38-25A6-4C53-B959-1176AB0CE952
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Srivicha Krudsood
@ast
Srivicha Krudsood
@en
Srivicha Krudsood
@es
Srivicha Krudsood
@nl
type
label
Srivicha Krudsood
@ast
Srivicha Krudsood
@en
Srivicha Krudsood
@es
Srivicha Krudsood
@nl
prefLabel
Srivicha Krudsood
@ast
Srivicha Krudsood
@en
Srivicha Krudsood
@es
Srivicha Krudsood
@nl
P106
P31
P496
0000-0002-0266-3575